Comparison of Vonoprazan-based Dual and Triple Therapies for H. Pylori Eradication

• Status: Completed
• Trial end date: 2019-03-31
• Target enrollment: 0
• Participant gender: All

Summary

Patients infected with H. pylori were randomly assigned to the dual therapy with vonoprazan 20 mg bid and amoxicillin 500 mg tid for 1 week or the triple therapy with vonoprazan 20 mg bid, amoxicillin 750 mg bid and clarithromycin 200 mg or metronidazole 250 mg bid bid for 1 week. Success or failure of eradication was determined by the 13C-urea breath test performed at 1 month after the therapy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hamamatsu University
• Treatments: Amoxicillin; Clarithromycin; Metronidazole

Criteria

Inclusion Criteria:

• Patients infected with H. pylori

• Patients who are not allergic to any of drugs used in this study

• Patients who agree to participate to the study patients who are treatment naive for eradication of H. pylori

Exclusion Criteria:

• Patients not infected with H. pylori

• Patients who are allergic to any of drugs used in this study

• Patients who do not agree to participate to the study

• Severe general condition, such as renal insufficiency or liver dysfunction

• History of gastrectomy

• Inability to undergo eradication therapy

• Patients who have ever undergone the eradication therapy for H. pylori infection